# CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer

> **NCT00075192** · PHASE1,PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 8 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** CP-675,206 and leuprolide acetate and bicalutamide
- **DRUG:** leuprolide acetate and bicalutamide

## Key facts

- **NCT ID:** NCT00075192
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2006-03
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2012-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00075192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00075192, "CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00075192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*